Sage Therapeutics' (SAGE) CORAL Phase 3 Study Likely to Meet Primary Endpoint, But Not Enough to Drive Stock Higher - Needham & Company

January 18, 2022 6:15 AM EST
Get Alerts SAGE Hot Sheet
Price: $31.93 +0.82%

Rating Summary:
    14 Buy, 12 Hold, 0 Sell

Rating Trend: = Flat

Today's Overall Ratings:
    Up: 14 | Down: 24 | New: 13
Trade Now! 
Join SI Premium – FREE

Get instant alerts when news breaks on your stocks. Claim your 1-week free trial to StreetInsider Premium here.

Needham & Company analyst Ami Fadia reiterated a Buy rating and $85.00 price target on Sage Therapeutics (NASDAQ: SAGE)

The analyst quotes: "In this note we preview the upcoming CORAL Phase 3 data readout for zuranolone + ADT vs ADT alone in MDD in early 2022. We believe that there is a high likelihood for the study to meet its primary endpoint of reduction in HAMD at day 3; however, that alone is unlikely to drive a positive move in the stock. From an investor's perspective, we think the day 15 and day 42 secondary endpoints are a greater focus, and will be important for continued momentum in the stock. As discussed inside the note, we believe the study has a good chance of hitting the endpoint at day 15 and will likely show a continued trend at day 42 (unlikely to be stat sig.)"

For an analyst ratings summary and ratings history on Sage Therapeutics click here. For more ratings news on Sage Therapeutics click here.

Shares of Sage Therapeutics closed at $42.92 yesterday.

Written by Vlad Schepkov | [email protected]

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, Trader Talk

Related Entities

Needham & Company, Vlad Schepkov